MAYOLY strengthens healthcare sovereignty by relocating colchicine production to its Auxerre site in France.

MAYOLY has reached a new milestone in its industrial and healthcare sovereignty strategy by relocating the production of colchicine, an essential treatment for gout, to its Auxerre site (Galien – Bourgogne-Franche-Comté).

Used by approximately 600,000 patients, colchicine is a critical medicine whose supply security is of major importance. In a context of global supply chain tensions, this relocation will help sustainably secure the production and distribution of this essential treatment.

The project includes a €2.5 million investment to bring this strategic production back in-house in France and will contribute to:

  • supporting employment and industrial expertise in local communities;
  • promoting responsible, competitive and sustainable French manufacturing;
  • strengthening industrial autonomy and healthcare sovereignty.

Today, 85% of MAYOLY’s products are manufactured in France, the Group operates in more than 100 countries worldwide, and generates over €400 million in exports.

The announcement was widely covered by both national and regional media, including Le Monde, La Tribune, Le Figaro, France 3 Régions, 20 Minutes, Sud Ouest, Nice-Matin, L’Usine Nouvelle, Challenges, France Bleu Auxerre, L’Yonne Républicaine, Économie Matin and Boursorama.

 

Article Le Monde

Article La Tribune

Article Le Figaro

Article Challenges

Article L’Usine Nouvelle

Article 20minutes

Article France 3 Régions

Article l’Yonne Républicaine

Article Sud Ouest

Article Nice Matin

Article Radio France

No comments yet, be the first to comment.

Leave a Reply